Neurocrine Biosciences (NBIX) Other Non-Current Liabilities (2010 - 2026)

Neurocrine Biosciences has reported Other Non-Current Liabilities for 17 years, with the latest figure at $297.7 million in Q2 2026.

• Other Non-Current Liabilities for Q2 2026 came in at $297.7 million, up 41.69% year-over-year; the trailing twelve-month figure through Jun 2026 was $297.7 million (up 41.69% YoY), and the FY2025 annual result was $219.7 million, up 32.19% from the prior year.
• Other Non-Current Liabilities improved to $297.7 million in Q2 2026, from $260.9 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $297.7 million in Q2 2026 and troughed at $17.1 million in Q3 2022.
• A 5-year average of $129.3 million and a median of $127.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The widest annual swing landed in 2022, when Other Non-Current Liabilities dropped 7.51%; it then jumped 301.17% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $29.7 million in 2022, then surged by 257.91% to $106.3 million in 2023, then surged by 56.35% to $166.2 million in 2024, then soared by 32.19% to $219.7 million in 2025, then jumped by 35.5% to $297.7 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $297.7 million in Q2 2026, $260.9 million in Q1 2026, and $219.7 million in Q4 2025.